Bristol-Myers: clinical collaboration with Vedanta
(CercleFinance.com) - Bristol-Myers Squibb has announced a new clinical collaboration with Vedanta Biosciences to evaluate the combination of its flagship product Opdvivo with Vedanta's VE800 in patients with advanced or metastatic cancers.
Opdivo is a programmed death-1 immune checkpoint inhibitor that is designed to harness the body's own immune system to help restore anti-tumour immune response.
Still at an experimental level, VE800 is an oral immuno-oncology product that activates T cells, a type of white blood cell that is the predominant effector in cancer immuno-therapy.
As part of the agreement, Bristol-Myers Squibb currently intends to make an equity investment in Vedanta Biosciences.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Opdivo is a programmed death-1 immune checkpoint inhibitor that is designed to harness the body's own immune system to help restore anti-tumour immune response.
Still at an experimental level, VE800 is an oral immuno-oncology product that activates T cells, a type of white blood cell that is the predominant effector in cancer immuno-therapy.
As part of the agreement, Bristol-Myers Squibb currently intends to make an equity investment in Vedanta Biosciences.
Copyright (c) 2018 CercleFinance.com. All rights reserved.